.
Search
Dr. Dan Judge and Dr. C. Michael Gibson discuss new findings from a study evaluating the differential stabilization of transthyretin (TTR) with acoramidis and tafamidis. The study found greater TTR stabilization with acoramidis across multiple analyses, including in vitro testing of 51 patient samples representing 17 unique TTR variants.
Sponsored by an independent educational grant from BridgeBio Inc.
New insights into the heart-kidney connection in ATTR-CM. Dr. Jeffrey Testani and Dr. C. Michael Gibson discuss new analyses showing that acoramidis was associated with early and sustained kidney-protective effects in patients with ATTR-CM—findings that may help explain the therapy’s early cardiovascular benefits and offer new perspectives on cardiorenal health.
Supported by an independent educational grant from BridgeBio Inc.